Sci Transl Med: Scientists have successfully engineered common yeasts to treat Thyrobacter difficile infections

November 3, 2020 // -- In a recent study published in the international journal Science Translational Medicine, scientists from the University of Maryland and other institutions studied mice and found that modifying common types of yeast in a specific way may be effective In the paper, the researchers describe how the specific antibodies produced by Saccharomyces boulardii are used to tohom the toxins produced by modifying Saccharomyces boulardii, while the researchers also describe how and how this particular antibody works.
Thyrobacteria infections usually occur in people who take antibiotics to treat bacterial infections, especially in the elderly, and when antibiotics kill beneficial bacteria in the intestines, the intestines become susceptible to Tracy Difficile infections, which are common in homes for the elderly and in some hospitals, and are common in the United States About 30,000 deaths have been caused, and the treatments used in the clinic are mainly more antibiotics, and when antibiotics are effective against Thyrobacteria infections, researchers worry about the results of bacterial resistance, and in this study, researchers found a new way to protect against Thyrobacteria infection without antibiotics.
Photo Source: CDC researchers say the new method involves using antibodies to fight two toxins produced by Clostridium difficile, which is the most common yeast in many probiotic supplements when they engineer brass yeast to make this particular antibody Using antibiotics to kill the mice's gut biome backward, the researchers fed the mice antibodies produced by Brass yeast, and then infected the mice with Clostridium difficile, and found that the intake of antibodies reduced the inflammatory response of the mouse's intestines, while also protecting the mice from death.
researchers noted that they first treated mice and then reused Thyrobacteria infection, which was found to reduce symptoms of disease in mice and effectively prevent death in mice, and when the mice' colon tissue was analyzed, the researchers found that the new strategy not only reduced inflammation in mice, but also inhibited tissue damage associated with Thyrobacteria infection.
researchers say they need to do more testing later in the day before entering clinical trials, and later they will develop new therapies that are more effective at suppressing Thoresium difficile infections based on this paper.
() Original source: Kevin Chen, Yixuan Zhu, Yongrong Zhang, et al. A probiotic yeast-immunotherapyst Clostridioides difficile, Science Translational Medicine (2020). DOI: 10.1126/scitranslmed.aax4905